Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Stay focused on the facts

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Mar 23, 2022 11:02am

80 Views

Post# 34537687

RE:RE:RE:Stay focused on the facts

And lost their suit as well. Don't be that person.

Trogarzon wrote:
Maybe the seller is the one that will look and feel really bad in not too long. I recall the pre Egrifta approval period in 20210.... the seller sued Thera for their losses.

<< Previous

Bullboard Posts

Next >>

Nintendo stock jumps despite Q2 financials, new console news